NEUROBLASTOMA UK
FIGHTING CHILDHOOD CANCER
NEUROBLASTOMA UK
Charity Commission referen￿ number: 326385
REPORTS AND FINANCIAL STATEMENTS
For the year ended 31 December. 2025

NEUROBLASTOMA UK
REPORT AND FINANCIAL STATEMENTS
For the year ended 31 December, 2025
CONTENTS
Page
Trustees, annual report
Indep8ndenl Examiner's Report
SlateneTrt of Financial AclNilies
Balance sheet
Notes lo the financial ststements
9-12

TRUSTEES. ANNUAL REPORT for the year to 31 December. 2025
The Trustees present their report wtth the financial statements of the Charty for the year ended 31 December
2025. The Trustees have adopted the provisions of Accounting and Reporting by Charities.. Statement of
Recommended Practice applicable to charities preparing their accounts in accordance with the Financial
Reporting Standard applicable in the UK and Republic of Irelalld IFRS102) (effective 1 January. 20151. As a
charity registered in England and Wales. the Charity also reports in accordance with the Charity Commission for
England and Wales, guidan￿ on public benefit and the Charities Act 2015.
Section A
nc
mini
iv
Charity Name
NEUROBLASTOMA UK
Registered Charity Number
326385
Registered Address
Canopi. 82 Tanner Street. London SE13GN
Trustees who manage the Charity:
Zara Ailchison (Cfrchairl
Tori Eadinglon (Secretary)
Malcolm Dean (Treasurer)
Clair Cliff (Treasurer)
Ruby Dickens
Stephen Smith
DeborahTweddle
Faye Watts
Kate Wheeler (Co-chair)
Martin Elliott
Independent Examiner
DJH L5verpool Limited. Statutory Auditor. 3rf Flcw Pacific Chambets. 11-13
Victoria StreeL Liverpod. L2 5QQ
Bardays Bank PLC. Newmarkel, LE87 28B
Bankers
Public Benefit Requlrement
The Iruslees of Neuroblastoma UK confimi that they have complied with their duty to have due regard lo Ihe
guidan￿ on public benefit published by the Charity Commission in exercising their powets or duties.
Section B
StTUCt
re
ov
mance and man
ernen
Governing Docurnent
The Trust is an unincorporated trust. constiluted under a Trust Deed dated 20 May. 1983 and by the
supplernental Deed of Amendment 9th September 2016 and is a registered Charity number 326385 in England
and Wales.
Recruitment and appointment of new trustees
Lay TnJstees are appointed by the Trustees following considerab.on of appltcations received from individuals.
Medical Trustees are appointed by ihe Trustees on the recommendation of existing Medical Trustees.
Risk Management
Trustees have considered the major risks to which the Charity may be exposed.. have reviewed them and
estsbli5hed systems and procedures to manage them. Tnjslees consider the possibility that money placed on
investment could be al risk if the organisalion holding the deposit should fail. Athough current investments are
placed with large. well-eslablished financial institutions Trustees identified the need lo re-examine investment
policy and have concluded that investments should be spread across a nurnber of institutions lo minimise the

impact if a single fund-holder should fail. The Trust is essenlially a cash based charity, holding no property. The
Charity has developed sufficient inlemal controls to monitor and minimise the risk of misappropriation of funds.
Section C
es
Oblectives and Alms
The object of the Charity is to improve treatments and outcomes for all children suffefing with neuroblasloma.
and lo achieve this we raise funds for vital mediral ￿searCh. The Charity also raises awareness of the disease,
advocates for impmved accessibility to treatments and provides infomiatH)n and support to families.
Policy on Grant-making
Trustees invite applications for grant awards by public advertisement. typically on the Charity's website.
Normally this is biennially so that sufficient funds are available to mmmission meaningful research studies,
although exceptions are Occasion￿lY made when judged appropriate by ￿ Trustees in consullalion with the
Charity's Scientific Advisory Board {SAB}- Applications are first considered by the Charity's SAB. which is made
up of 5 scientists eXperien￿d in Neuroblasloma research and a chairnlan who is a paedialric oncology
clinician. Each application is accompanied by reports from 2 or 3 referees who have specialist kno￿edge of the
research area proposed, and by a response from the applicants to those reports. The SAB then recommends to
Trustees applicaliorbs Worthy of grant funding in order of me¥it. Trustees award grants in the light of the SAB'S
advice and funds available. Grants are only awarded to the extent that reswrces have already accrued in the
Charity's unrestricted fijnd or appropriate restricted fvnd.
Sgction D
en
nco
Charitable Activitias
2024 was a year of signtficant spend for the Charity after hosting the Neuroblasloma UK Symposium and
funding in excess of £1.1 m in new research studies for Neuroblasloma.
The objective for 2025 was to replenish fu￿￿$ whilst continuing to advocate on behaw of the neuroblasloma
community. raise awareness and fund small innovation sludies whilst building up our reserves for the next
major grant round which we hope will be in 2027.
We are delighted that our major research studies that were awarded at the end of 2024 , have all commenced
during 2025 and will continue over the next 24 yeats . We received a grant to put towards our commitment to
Professor Archibald's study al KCL in improvements in PET imaging of £125.(MJO (£62,500 in 20025 and the
rest we should receFve in 2026 YOA) from Sofving Kbjs. Cancer UK suw)rted by funding from Children wrlh
Cancer UK.
We rebranded our 'Sm811 Granls. as 'lnnovation Grants. to reflect the inspiring novel applications that we
receive. which often test bold new ideas. These grants. although small. have shown swjnificant impact and often
act as ' proof of principle. research that ran pave the way for larger dinical studies. We awarded funding for 3
new studies in 2025.
(£2,000 lo the ICR to invesligale better drug combination strategies for high risk neuroblastoma.Using
advanced 3D tumour models to test combinations of ALK-blocking d￿￿S with ATR inhibitors to see which are
the most effective against chemotherapy resistant tumours.
£4.970 to University of Southampton to investigate t￿sting immune cel therapies for neuroblastoma which
could strengthen future immunotherapy approaches.
We were grateful for support from the Grocers Charity of £5.000 which funded Dr Wang's research also at
Soulhamplon. This team of researchers r￿ntlY discovered three sub groups within neuroblasloma that do not
have MYCN amplification and this grant enabled them to IcN)k into polential new treatments for these sub
groups.)
Also in 2025 , we committed funding to support the BIOPORTAL project in excess of £25.000- the first UK data
repository for children with neuroblastoma
.A new edib.on of our free "Parents Guide lo Neuroblastoma" and our factsheel-Treatrnent options for relapsed
or refractory high llsk neuroblastoma". online and in print. in collaboration with Children's Cancer and
Leukaemia Group and Solving Kids Cancer UK . was released.

From an advocacy perspective we supported the Rare Cancer Bill and are delighted that it has now been given
the final approval by the House of Lords. This calls for a look at unJenl dispartties in care . research and survival
outcomes of Can￿rS that are perceived as 'rare'.
We continue lo advocate as part of a collective voice with Can￿r 52 and One Cancer Voice. Neuroblasloma
UK were proud lo present alongside 60 other charities a bold. fully fvnded National Can￿r Plan to Downing
Street.
This year we reSt￿¢t￿red our staffing as a small fvnctional unit wtth a new management position. Along with
most charities, we have not been adverse to the tougher economic environment of the last few years and we
hope that this new structure will improve our fvndrdising margins through a dear focus on financi￿ targets and
a strengthened strategic brand management.
Our principal funding sources are voluntary donations and 2025 saw fundraising challenges from all over the
British 151es from Kiltwalkers in Glasgow to coastsl runs in Boumemouth and Co Antn"m and past thè sights in
London, Birmingham and more.The Three Peaks have been dimbed. 100km covered via bike,skydives
completed. ball room dances, santa runs elc. 89 supporters look part in our'100 Miles in September. Challenge
Comedy nights, bake sales and TedFesl our supporters have pulled out all the stops lo raise funds on our
behalf.
We are also grateful lo major donations from the John Biack Foundab'on. Robert Luff FourKlation and the Peter
John Foord Charitable Twst.
Significant fundraising events for us were the BBC Lifeline Appeal in January and February which aired on
8BC1 and the Big Give Christmas Ch￿lenge with thanks to Georgia's Fund and Can(lis Publications.
The major event of the year for the neuroblastoma communty was the final of'celebrity Traitors, watched by
over 12 million and won by our own patron, Ajan Carr. Not only did this mean that we were the receiver of the
prize pol bul over 137,000 people hit our website that night and 'neuroblasloma' was highlighted across the
media. Whilst Alan won playing a dastardly Traitcff . he is forever faithfvl to our Cause.
The Trustees express their gratitude to ALL parthefs . s￿nSorS . volunteers, families and supporters whose
amazing contributions have enabled Neuroblasloma UK to sustain and expand its work during the year. We
remain faithfijl to finding a cure for neuroblasloma.
Sectlon E
Financi
eview
Reserves Policy
The annual income generated by the Charity is to be applied for Charitable purposes in accordance with the
Trust's objective. Year on year the trustees intend to make a full distribution of available income, subject to
making adequate reserves for known and potential liabilities and commitments, where applicable. Any amounts
not so distributed are accumulated in the unrestricted fund. Funds committed to supporting approved research.
but not immediately required are invested in line wilh the investment poly described below. The balan￿ held
as unreslricled reserves al 31 December. 2025 was £105.77712024= 1£295,9471) and Trustees have agreed
that £70,000 of reserves must be held lover and above the grant commrtmentsl to support 6 months of
operalional expenditure.
Investment Policy
The Trustees, intention is lo maintain funds so Ihat they a￿ readily acce￿ble when required. bul are eaming a
reasonable r@tum whilst nol ulilised.Trustees reviewed this policy in February 2005 and confirmed their policy of
only placing funds in investments where the book value of the principal is maintained.
Statement of Trustees Responsibilitles

The trustees are ￿S￿nsIble for preparing the financial statements in accordan￿ with applicable law and
United Kingdom Accounting Standards (United Kingdom Generalty Ac￿pIed Accour7ting Practice).
Charity Law requires the Iruslees lo prepare financial statements for eath financial year. Under that law the
trustees have elected lo prepare the financial slalements in accordance wtth the United Kingdom generally
accepted accounting practi￿ (United Kingdom Accounting Stsndards. c(¥npnsing FRS 102'The financial
reporting standard applicable in the UK and Republic of Ireland.. and applicable lawl-The financial statements
are required by law to give a true and lair view of the stsle of affairs of the charity and ofthe surpius or deficit of
the charity for that period. In preparing ttr￿e financial ststernenls the tnjslees are required lo..
* select suitable accounting policres and then aptdy them consistenlly,
* observe the methods and prinryples in the Charibes SORP (FRS1021;
* make judgements and estimates that are reasonable and pruden(
+ slate whether applicable a(xounling standards have been followed. subpct lo any material departures
disclosed and explained in the financial statements- and
+ prepare the financial statements on the going concem basis unless it is inappropriate to presume that
the Charity will continue in business.
The Trustees are responsible for keeping proper accounting records whth disdose with reasonable accuracy
the firiancial position of the Charity and to enable them to ensure that Ihe finanfial statements comply with the
Charities Act 2011. the Charity (Accounts and ReFJOrts) Regulations 2008 and Ihe provisions of the trust deed.

They are also responsible lor safeguarding the assets of the Charity and hen￿ for taking reasonable steps for
the prevention and detection of fraud and other irregularities.
Signed on their behalf and with their approval by..
MRS ZAITCHISON
Chair
MS CLAIR CLIFF
Tnjslee and Treasurer

Independent Examlner's Report to the Trustees of Neuroblastoma UK
I report to the trustees on the examinats.on of the accounts of NeuroblastomA UK for the year ended 31
December, 2025..
Respective Responsibilities of Trustees and Examiner
The Charity's Iruslees are responsible for the preparation of accounts in accordance with the requiremenls of
the Charities Act 2011.
I have reported in respecl of the examination of the Charitys accounts carried out under section 145 of the 2011
Act and in carrying out the examination have followed all the applicable Directions given by the Charity
Commission under section 145{51{bl of the Act.
Independent Examiner's Ststement
The Charity's gross income extEeded £250.0￿ and l am qualrfied to undertake the examinalion by being a
qualified member of ICAEW.
I have completed the examination and can confirm that no material matters have come lo my attention in
connection with the examinab'on. which gives me reasonable cause to believe that in, any material respect..
the accounting records were not kept in accordance with sectton 130 of the Charities Act 2011.,
the accounts did not accord with the aceounting records" or
the accounts did not comply wih the applicable requirements con￿MIng the form and content of
accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement
that the accounts give a 'true and fair, view which is not a matter considered as part of an independent
examination.
I have no cOn￿M$ and have come auoss no other matters in CA)nnection with the examination lo which
attention should be drawn in this report in order to enable a proper understanding of the aC￿UnIS lo be
reached.
Mr M J Forshaw BA FCA
DJH Liverpool Limited
Pacific Chambers
11-13 Vidoria Street
Liverpool
L2 5QQ

NEUROBLASTOMA UK
STATEMENT OF FINANCIAL ACTIVITIES
YEAR ENDED 31 DECEMBER 2025
Unrestricted Funds
31 December. 2025
Unrestricted Funds
31 De￿rnber, 2024
Note
INCOME AND ENDOWMENTS FROM:
Donations
393.910
209,846
Other trading activities
52.628
46,985
Income from investments
44,459
46,519
TOTAL
490.997
303,350
EXPENDITURE ON:
Raising funds
11,717)
1464)
Charitable activities:
Grants payable and grant amendments
29,178
11.012.496}
Govemance costs
1116.734)
1172,3851
TOTAL
{89.273)
(1.185,345)
NETINCOME/(EXPENDITURE)
401.724
(881,9951
RECONCILIATION OF FUNDS
Total funds brought forward
{295.947)
586,048
TOTAL FUNDS CARRIED FORWARD
105.777
1295,9471
10

NEUROBLASTOMA UK
BALANCE SHEET
AS AT 31 DECEMBER 2025
2025
2024
Note
CURRENT ASSETS
Debtors and advance payments
17.730
24,664
Inveslnenls
10
1.083.649
1,250,792
Cash al bank
11
260.$30
100,743
TOTAL CURRENT ASSETS
1,361.909
1,376,198
CREDITORS." Amounts falling due within
one year
12
{346.170)
1483,564)
NET CURRENT ASSETS
1.015.739
892,634
CREDITORS.. Amounts falling due in more
than one year
13
(909.962)
{1.188,5811
NET ASSETS
105.777
1295,9471
FUNDS OF THE CHARITY
Unrestricted fund
15
105,7ri
(295.947)
The financial statements sel out on pages 8- 13 were approved by the Trthstees on 23rd of July 26:
TRUSTEE- Mrs Z Aitchison
TRUSTEE- MS C Clair
11

EUR
BLAST
MA
NOTES TO THE ACCOUNTS
YEAR ENDED 31 DECEMBER 2025
ACCOUNTING POUCIES
Basis of preparing the financial statements
The financial ststemenls of the tharilable trust. whrch is a putAic trenefft entity under FRS 102, have
been prepared in accordance with the Chalilies SORP (FRS102) 'Accounting and Reporting by
Charities- Slalemenl of Recommended Practice applicable lo charities preparing their accounts in
accordance with the Financial Reporting Stsndard applicable in the UK and Republic of Ireland
IFRS1021 leffeclive 1 January. 2015).. the Finan(ial Reporttng Standard 102 (effective January 2015)
and the Charities Act 2011. The finanaal statements have been wepared under the historical cost
convention.
Donations
Cash donations and gift5 are included in full in the Statement of Financial Activities when they are
received by the Charity. Cash collected al special fund-raising events included in the income and
expenditure account after deducling the expenditure incurred directfy in staging the event. Significant
non-cash donations are induded in the irtcome and expenditure aco)unt at the Trustees. estimation of
their market value when received.
Income from investments
Investment income is induded in the Statement of Finan￿81 Acbvitres on an accruals basis.
Research grant awards
These are Charged to the Ststemenl of Finanoal Activtiies when the Tnjslees have awarded them.
Research grants awarded. bul not disbursed at the balance sheet date. are carried forward as grant
creditors in the balance sheet.
Fund accounting
Unrestricted fvnds can be used in accL)rdance wth the charitable cbjectives at the discretion of the
trustees.
Reslricled fijnds can only be used lor p8rts"cular restricted purposes wrthin the objects of the charity.
Reslriclions arise when Sp￿tfied by the don￿ or when funds are ￿Sed for parti¢Lrlar restricted
purpDses.
Further explanation of the nature and purpose of each fund Is inclL*Jed in the notes to the financial
statements.
Cash Ilow statements
The Charity has taken advantage of the exemption provmled by the ch8rib.es SORP {FRS102) and
does not prepare a cash ffow statement
Taxation
The Charity is exempt from tsxakn on its charttable activib"es.
VAT
As a non-trading organisation. the Charty is not registered for VAT purposes and is unable to recover
VAT incuffed on its expenditure.
12

NEUROBLASTOMA UK
ENDED 31 DEC
025
DONATIONS
2025
2024
Donations and fund-raising
393.910
209,846
OTHER TRADING ACTivfTIES
2025
2024
Christmas cards, webshop and other income
52,628
46.985
INCOME FROM INVESTMElffS
2025
2024
COIF deposit
National saving5 income bonds
32,857
33.315
44.459
46,519
EXPENDrruRE ON RAISING FUNDS
2025
2024
Fund-raising a￿1 publicity Costs
1.717
464
GRANTS PAYABLE AND GRANT AMENDMENTS
2025
2024
Contribution from Medical Research Council
Archibald
Chesler
Falconer
Piskareva
Stoker
Wrillen Off
Small Grants
189,8571
268.301
254,120
188,039
208,887
183,207
(62.500)
33.322
(29.1781
201
1.012,496
13

NEUR
BLAST
MAUK
NOTES TO THE ACCOUNTS
Contin
ed
YEAR ENDED 31 DECEMBER 2025
EXPENDITURE ON CHARITABLE ACTivmES
2025
2024
Rent and facilits.es
Cambridge Symposium
Staff salaries and penston contributions
Sporting event costs
Subscriplicffis
Travel
Computers. software and equipment hire
Accounts and audit
Tnjslees meeting costs
Printing, postage and stationery
Legal fees
Sundries
Advertising and website
Insurance
Bank and professional charges
8,310
8,573
38,893
96,072
5.407
4.734
76,T75
6.988
20
6.212
840
9,027
840
714
262
1,869
1.926
1.003
919
2.787
1.226
9,310
116,734
1.202
982
172.385
TRLISTEES, REMUNERATION AND BENEFITS
There was no tTUStees' remuneration or other benefrts for the year ended 31 December, 2025
12024.. £NILI.
The Trust owns no premises.
DEBTORS AND PREPAYMEKrs
2025
2024
Receivables
Prepayments
Co-funding income
1,188
2,292
14.250
1.188
4,226
19,250
17,730
24,663
10.
CURRENT INVESTMENTS
14

UROB
STOMA
NOTES TO THE ACCOUTrtrs
Continued
YEAR ENDED 31 DECEMBE
2025
11.
CASH AT BANK AND IN HAND
2025
2024
Cash al Bank
260 530
100 742
12.
CREDITORS- DUE WITHIN ONE YEAR
2025
2024
Grant commitments
Trade creditors
Accruals
Co-funding income re￿Ned in advan
300.654
4,202
26.314
465.696
1,966
900
15,000
346.170
483.562
13.
CREDITORS- DUE IN MORE THAN ONE YEAR
2025
2024
Grant commitments
909.962
1,188,581
14.
GRANT COMMITMENTS
2025
2024
Totsl commitments at 1 January. 2025
Paid in the year
New commilments
1.654.479
1450,8041
7,142
670,328
1118,403}
1.102.554
1.210.817
1.654.479
All of the new grant commitrnents are to institutsons.
15.
ANALYSIS OF UNRESTRICTED FUND
2025
2024
At 1 January. 2024
Net movement in funds for the year
1295.947)
401 724
586.048
881 995
105,77T
{295,9471